目的 探讨黑地黄丸治疗慢性肾脏病肾性贫血患者的疗效及对其铁代谢的影响.方法 选取2020年6月 2022年6月期间我院肾内科门诊及住院部收治的80例肾性贫血患者为研究对象,采用随机数字表法分为对照组和观察组,每组各40例.对照组采取常规治疗,观察组在对照组基础上予以黑地黄丸口服,两组患者均持续治疗12周.观察比较两组患者临床疗效、不良反应,治疗前后中医证候积分、贫血纠正情况[红细胞数(Red blood cell,RBC)、血红蛋白含量(Hemoglobin,HGB)、红细胞压积(Hematocrit,HCT)]、铁代谢指标[血清铁蛋白(Se-rum ferritin,SF)、血清铁(Serum iron,SI)、总铁结合力(Total iron bond strength,TIBC)和转铁蛋白饱和度(Transferrin saturation,TAST)]、肾功能指标[血清尿素氮(Serum urea nitrogen,BUN)、肌酐(Serum creatinine,Scr)、计算肾小球滤过率(Estimated glomerular filtration rate,eGFR)].结果 治疗后两组患者中医证候积分较治疗前明显降低,差异有统计学意义(P＜0.05);且观察组中医证候积分明显低于对照组,差异有统计学意义(P＜0.05).治疗后两组患者RBC、HGB及HCT指标均较治疗前明显升高,差异有统计学意义(P＜0.05);且观察组RBC、HGB及HCT指标明显高于对照组,差异有统计学意义(P＜0.05).治疗后两组患者SF、SI及TAST指标均较治疗前明显升高,TIBC指标明显降低,差异有统计学意义(P＜0.05);且观察组SF、SI及TAST指标明显高于对照组,TIBC指标明显低于对照组,差异有统计学意义(P＜0.05).治疗后两组患者BUN及Scr指标均较治疗前明显降低,eGFR指标较治疗前升高,差异有统计学意义(P＜0.05);且观察组BUN及Scr指标明显低于对照组,eGFR指标明显高于对照组,差异有统计学意义(P＜0.05).治疗后观察组总有效率(92.5％)明显高于对照组(75％),差异有统计学意义(P＜0.05).治疗期间,两组患者不良反应比较,差异无统计学意义(P＞0.05).结论 黑地黄丸能够纠正CKD肾性贫血患者铁代谢紊乱,改善铁代谢,继而减轻患者临床症状,改善贫血情况,最终改善患者肾脏功能,提高临床疗效,且具有较高安全性,值得推广.
Efficacy of Heidihuang Pills on Renal Anemia Patients with Chronic Kidney Disease and Effect on Iron Metabolism
Objective To investigate the efficacy of Heidihuang Pills in treating renal anemia in patients with chronic kidney disease(CKD)and the impact on iron metabolism.Methods Eighty inpatients and outpatients with renal anemia treated at Nephrology Department of Tai'an Hospital of Traditional Chinese Medicine from June 2020 to June 2022 were selected and randomly divided into a control group and an observation group according to a random number table,with 40 patients in each group.The control group received conventional treatment,while the observation group received Heidi-huang Pills orally in addition to the conventional treatment.Both groups were treated for 12 weeks.The clinical efficacy,ad-verse reactions,traditional Chinese medicine(TCM)syndrome scores,anemia correction parameters[red blood cell count(RBC),hemoglobin content(HGB),and hematocrit(HCT)],iron metabolism indicators[serum ferritin(SF),serum iron(SI),total iron binding capacity(TIBC),and transferrin saturation(TAST)],and renal function indicators[serum urea ni-trogen(BUN),serum creatinine(Scr),and estimated glomerular filtration rate(eGFR)]in both groups were compared be-fore and after treatment.Results After treatment,TCM syndrome scores significantly decreased in both groups compared to those before treatment(P＜0.05),with the observation group showing significantly lower scores than the control group(P＜0.05).RBC,HGB,and HCT levels significantly increased in both groups compared to those before treatment(P＜0.05),with the observation group showing significantly higher levels than the control group(P＜0.05).SF,SI,and TAST levels significantly increased,and TIBC significantly decreased in both groups compared to those before treatment(P＜0.05),with the observation group showing higher SF,SI,and TAST levels and lower TIBC levels than the control group(P＜0.05).BUN and Scr levels significantly decreased,and eGFR significantly increased in both groups compared to those before treatment(P＜0.05),with the observation group showing lower BUN and Scr levels and higher eGFR than the control group(P＜0.05).The overall efficacy rate in the observation group(92.5％)was significantly higher than in the control group(75％)(P＜0.05).There were no significant differences in adverse reactions between the two groups during the treatment period(P＞0.05).Conclusion Heidihuang Pills can correct iron metabolism disorders in renal anemia pa-tients with CKD,improve iron metabolism,alleviate clinical symptoms,improve anemia,and ultimately enhance renal func-tion and clinical efficacy.The treatment is safe and worthy of promotion.
Heidihuang PillsChronic Kidney DiseaseRenal AnemiaIron MetabolismRenal Function
万方数据
维普
